YD Bio

YD Bio FCF Yield

The Free Cash Flow Yield of YD Bio (YDES) as of Oct 16, 2026 is -1.56 %. In the previous year, Free Cash Flow Yield was -0.92 % — a change of 69.27% (lower).

FCF Yield

-1.56 %

YoY

69.27%

Last updated:

Free Cash Flow Yield of YD Bio is 2025 -1.56 % . Free Cash Flow Yield of YD Bio was 2024 -0.92 % . It decreases by 69.27% lower compared to the previous year.

The YD Bio FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2020
-0.05 USD
Jan 1, 2021
-0.13 USD
Jan 1, 2022
-0.59 USD
Jan 1, 2023
-0.01 USD
Jan 1, 2024
-0.92 USD
Jan 1, 2025
-1.56 USD
The YD Bio FCF Yield history
YEARFCF YieldYoY
-1.56 %+69.27%
-0.92 %+8,386.27%
-0.01 %-98.15%
-0.59 %+339.08%
-0.13 %+171.43%
-0.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YD Bio Stock analysis

What does YD Bio do? YD Bio Ltd is a company based in Taipei City, Taiwan, with its headquarters located in Taipei City. The company is set to go public on August 29, 2025, under the ticker symbol YDES and ISIN KYG983011076. YD Bio Ltd focuses on developing innovative solutions in the healthcare sector, particularly in early cancer detection and next-generation cell therapies. The company's core activities include creating non-invasive cancer detection tools for early diagnosis and monitoring, as well as developing ophthalmologic products for dry eye conditions. Additionally, YD Bio Ltd is engaged in exosome-based therapeutics designed to address complex diseases. The company aims to enhance patient outcomes and quality of life through the integration of advanced scientific research with practical, accessible healthcare solutions. YD Bio Ltd operates within the healthcare industry, though specific sector and industry classifications are not provided. The company's website is http://ir.ydesgroup.com/, where further information about its operations and future plans can be found. As a Taiwan-based entity, YD Bio Ltd contributes to the biotechnology and medical innovation landscape in the region. The company's IPO date is scheduled for 2025, indicating its readiness to expand its market presence and potentially scale its operations. YD Bio Ltd's mission centers on pioneering transformative healthcare solutions that improve and extend patient lives. YD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YD Bio stock

Free Cash Flow Yield of YD Bio is -1.56 % in 2025.

Free Cash Flow Yield of YD Bio changed from -0.92 % to -1.56 %, representing a 69.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield YD Bio since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's YD Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — YD Bio

All Key Metrics — YD Bio